NCT00229697 2015-10-05
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study
AstraZeneca
Phase 2 Completed
Clinical Trials
10 trialsNCT00077025 2014-07-16
Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer
AstraZeneca
Phase 2 Completed
NCT00252811 2011-01-28
A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer
AstraZeneca
Phase 2 Withdrawn
NCT00239343 2011-01-27
Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer
AstraZeneca
Phase 2 Completed
NCT00234403 2009-04-23
A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer
AstraZeneca
Phase 2 Completed
NCT00247481 2009-04-23
ZD1839 (Iressaâ„¢) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer
AstraZeneca
Phase 2 Completed
NCT00255463 2009-04-23
Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study
AstraZeneca
Phase 2 Completed
NCT00637026 2009-04-23
Ph II Early BC Pre-Surgical Biologic Study
AstraZeneca
Phase 2 Completed
NCT00632723 2009-04-22
IRESSAâ„¢ (Gefitinib) in Breast Cancer Patients
AstraZeneca
Phase 2 Completed
NCT00319618 2007-12-18
Combination Weekly Taxotereâ„¢ With Iressaâ„¢ /Placebo in Metastatic Breast Cancer
AstraZeneca
Phase 2 Completed